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Abstract 
Background: Abnormal miRNA expression was recently implicated in the metastasis of 
oral squamous cell carcinoma (OSCC) and with a poor prognosis. The initiation of the 
invasion-metastasis cascade involves epithelial-mesenchymal transition (EMT). Our 
aim was to clarify how miRNA, especially miR-155-5p misexpression contributes to 
OSCC metastasis through EMT.  
Methods: We collected tumor samples from 73 subjects with OSCC. The samples were 
analyzed by qRT-PCR, and correlations between miR-155-5p levels and clinical 
characteristics were investigated. OSCC cell lines were analyzed by miRNA microarray 
and by transfection with a miR-155-5p mimic or inhibitor, followed by proliferation and 
wound-healing migration assays. qRT-PCR analyses of EMT makers in cells transfected 
with miR-155-5p inhibitor were performed. 
Results: We found high miR-155-5p expression in tissue samples from subjects with 
OSCC that had metastasized to cervical lymph nodes. HSC-3 cells also strongly 
expressed miR-155-5p. The epithelial marker E-cadherin was strongly expressed in 
HSC-3 cells transfected with miR-155-5p inhibitor, and we observed elevated SOCS1 
and decreased STAT3 expression in these cells.  
Conclusions: Our results suggest that miR-155-5p causes OSCC to metastasize, and 
could serve as a novel therapeutic target for OSCC. 
  
Introduction 
Oral cancer accounts for 1-5% of all malignant tumors in humans (1-2), and oral 
squamous cell carcinoma (OSCC) comprises approximately 91% of all oral cancers (1). 
Despite advances in OSCC diagnosis and management, the Surveillance, Epidemiology, 
and End Results (SEER) data for 2011 show that the 5-year overall survival rate of 
patients with oral cavity and pharyngeal cancer has not significantly improved in the 
past decade (61.8%, 2002; 62.7%, 2011)(2). Clearly, we need more effective methods 
for diagnosing and managing OSCC.  
In general, metastasis strongly decreases the likelihood of a favorable 
outcome for cancer. Before cells in the primary tumor can metastasize, they must 
undergo epithelial-mesenchymal transition (EMT), in which epithelial cells change into 
mesenchymal cells; i.e., they lose cell polarity and cell-cell adhesion, and break free of 
neighboring cells, thereby acquiring the ability to metastasize via vascular invasion. 
Thus, EMT is a crucial early event in the invasion-metastasis cascade (3). 
Mesenchymal biomarkers include vimentin and neural cadherin (N-cadherin), 
which is also known as cadherin-2 (CDH2) (4). Vimentin is the primary cytoskeletal 
component of mesenchyme-derived cells or cells undergoing EMT. N-cadherin is 
commonly found in cancer cells; it frees cancer cells to metastasize by causing the 
failure of cell-cell adhesion (5). 
MicroRNAs (miRNAs) are short, non-coding RNAs consisting of 20-22 
nucleotides. A recent study showed that some miRNAs contribute to EMT induction (6). 
In addition, abnormal miRNA expression can lead to cancer and other diseases by 
suppressing the translation of the target gene's mRNA (7-11). OSCC-specific miRNAs 
have been identified (12), including miR-155. Although altered miR-155 expression in 
OSCC cells is known to alter OSCC cell behavior (13-15), its role in OSCC is not clear. 
Suppressor of cytokine signaling 1 (SOCS1) was recently identified as a novel miR-155 
target in breast-cancer cells. SOCS1 is a tumor suppressor that functions as a negative 
feedback regulator of Janus activated kinase (JAK)/signal transducer and activator of 
transcription (STAT) signaling (16), and STAT3 modulates the expression of EMT 
transcriptional factors, including Twist, Snail, Zeb1, Zeb2, and Slug (17-18).  
In this study, we found that miR-155-5p was significantly upregulated both in 
OSCC cell lines and in formalin-fixed, paraffin-embedded (FFPE) tissue samples from 
patients with OSCC metastases to cervical lymph nodes, which is associated with a poor 
prognosis. We also found that HSC-3 cells expressed increased levels of E-cadherin and 
decreased levels of N-cadherin and vimentin mRNAs when transfected with a 
miR-155-5p inhibitor. Furthermore, there was trend that SOCS1 was upregulated 
and STAT3 was downregulated in HSC-3 cells transfected with the miR-155-5p 
inhibitor.  
Our results showed that miR-155-5p expression correlated significantly with 
metastasis to the cervical lymph nodes in OSCC and with a poor prognosis. Our 
findings also suggest that miR-155-5p would be a potential novel target for the 
prevention of OSCC metastasis. 
 
Materials and methods 
Clinical samples 
The study included 73 patients with OSCC and 5 patients who did not have cancer. All 
subjects visited the University of Tsukuba Hospital for the first time between February 
2008 and November 2010, and tissue samples were collected on each subject's first visit, 
before administering treatment. Patients with oral cancers other than OSCC were 
excluded from this study. Samples of oral tumors were collected as part of a biopsy 
procedure. Thirty-four samples were from the tongue, 25 from the gingiva, 7 from the 
cheek, 4 from the floor of the mouth, and 3 from the soft palate. Five patients without 
OSCC who had an impacted wisdom tooth volunteered to provide an oral biopsy 
sample for this study. All control samples were from the gingiva around the wisdom 
tooth. The samples were prepared for FFPE histology using standard procedures. OSCC 
was diagnosed and classified based on the Tumor-Node-Metastasis (TNM) system of 
Unio Internationalis Contra Cancrum (UICC). All cases were diagnosed histologically 
and clinically, as confirmed by pathologists. The median follow-up period was 24 
months (range, 3–50 months).  
Table 1 shows the clinical characteristics of subjects with OSCC. Follow-up 
data were obtained from each patient's medical chart. Disease-free survival time was 
calculated from the date of the patient's first visit to a final time point of 60 months, 
when the overall survival rate was poor.   
This study was reviewed and approved by the Ethics Committee University of 
Tsukuba Hospital (No.215). All patients gave informed written consent prior to 
enrollment. 
 
Cell lines, reagents, and cultures 
HaCaT and HSC-3 cell lines were obtained from the Japanese Collection of Research 
Bioresources. HSC-3 is a human oral squamous carcinoma cell line with high metastatic 
potential. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (Nichirei Bioscience, Tokyo, Japan) and 1% 
penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
HaCaT cells, an immortalized human keratinocyte line, were used as a control. 
 
TaqMan-based quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
assays of miRNA expression 
Mature miRNA expression levels were analyzed by TaqMan miRNA assay. 
Total RNA was extracted with the miRNeasy Mini Kit (Qiagen, Venlo, Limburg, 
Netherlands) for cell lines and the miRNeasy FFPE Kit (Qiagen). Total RNA was then 
reverse-transcribed into complementary DNA using a TaqMan MicroRNA 
Reverse-Transcription Kit (Applied Biosystems, Foster city, CA). The miR-155-5p level 
in the HSC-3 cell line was compared with the level in HaCaT cells. PCR reactions were 
first incubated at 16°C for 30 min and then at 42°C for 30 min, followed by inactivation 
at 85°C for 5 min. For the miRNA microarray analysis, reactions were then incubated in 
an miRNA PCR array platform (Human Cancer Pathway Finder miScript miRNA PCR 
array, MIHS-102Z, Qiagen), and other samples were incubated in a 384-well plate at 
50°C for 2 min and at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 
60°C for 1 min, using the 7500 Fast Real-Time PCR System (Applied Biosystems) for 
MIHS-102Z, and the CFX384 Real-Time System (Bio-Rad Laboratories, Pleasanton, 
CA, USA) for 384-well plates. Relative miRNA expression was normalized against 
SNORD95 in the miRNA microarrays, and other samples were normalized against 
RNU-6B. Relative expression was calculated by the comparative threshold (CT) method. 
All experiments were performed at least in quintuplicate.  
 
TaqMan-based qRT-PCR assays of mRNA expression 
The qRT-PCR primers for E-cadherin, N-cadherin, and vimentin mRNA were as 
described previously (19-21): E-cadherin, 5’-TGCCCAGAAAATGAAAAAGG-3’ 
(forward) and 5’-GTGTATGTGGCAATGCGTTC-3’ (reverse); N-cadherin, 
5’-ACAGTGGCCACCTACAAAGG-3’ (forward) and 
5’-CCGAGATGGGGTTGATAATG-3’ (reverse); vimentin, 
5’-GAGTCCACTGAGTACCGGAGAC-3’ (forward) and 
5’-TGTAGGTGGCAATCTCAATGTC-3’ (reverse); SOCS1, 5′-GAGGGAGC 
GGATGGGTGTA-3′ (forward) and 5′-GAGGTAGGAGGT GCGAGTTCAG-3′ 
(reverse); and STAT3, 5′-CCAAGGAGGAGG CATTCG-3′ (forward) and 
5′-ACATCGGCAGGTCAATGG-3′ (reverse). Total RNA was extracted with the 
RNeasy Mini Kit (Qiagen) and then reverse-transcribed into complementary DNA using 
a PrimeScript RT Reagent Kit (TaKaRa, Shiga, Japan). PCR reactions were first 
incubated at 16°C for 30 min and then at 42°C for 30 min followed by inactivation at 
85°C for 5 min. Reactions were then incubated in a 384-well plate at 95°C for 20 s, 
followed by 40 cycles of 95°C for 3 s and 60°C for 30 s using the CFX384 Real-Time 
system (Bio-Rad Laboratories). Relative mRNA expression was normalized against 
GAPDH. Relative expression was calculated by the comparative threshold (CT) method. 
All experiments were performed at least in quintuplicate. 
 
Transfection with miR-155-5p mimic or inhibitor  
Cells were transfected with miR-155-5p mimic or inhibitor or with scrambled negative 
control (NC) (Ambion, Austin, TX, USA) using Lipofectamine RNAiMAX (Invitrogen, 
Carlsbad, CA). Twenty-four hours after the beginning of the transfection, we isolated 
RNA and assayed cell proliferation and wound-healing migration. 
 
Cell-proliferation assay 
HSC-3 cells were seeded in triplicate 6-well plates with 3 mL of cell suspension per 
well (total 2.5 × 105 cells/well) and incubated for 24 h to allow attachment. The cells 
were transfected with miR-155-5p mimic or inhibitor or with NC, and were counted 24 
h and 48 h after transfection using a TC10 (Bio-Rad) automated cell counter. 
 
Wound-healing migration assay 
HSC-3 cells were seeded in 6-well plates with 3 mL of cell suspension per well (total 
2.5 × 105 cells/well), cultured until approximately 80% confluent, and then transfected 
with miR-155-5p mimic or inhibitor or with NC. Twenty-four hours later, the cells were 
washed twice with phosphate-buffered saline (PBS), starved by incubation in 
serum-free medium for 24 h, and then a wound was simulated with a straight scratch 
using a 200-μL pipette tip. The cells' migratory ability was measured by photographing 
the wound area every 3 h and quantifying it by ImageJ software. All experiments were 
performed at least in duplicate. 
 
Statistical analysis 
Data from the OSCC cell line were compared by the Student’s T test. Data from the 
FFPE tissue samples were compared by the Mann-Whitney U test. Data from the 
Student’s T test are presented as the mean + standard deviation (SD), and data from the 
Mann-Whitney U test are presented as boxplots. Data from cervical lymph-node 
metastasis and disease-free survival data were analyzed by the Chi-square test. Survival 
data were analyzed by Kaplan-Meier survival analysis; Kaplan-Meier curves were 
compared using the log-rank test. In Chi-square tests and the Kaplan-Meier survival 
analysis, the miR-155-5p expression level was classified as high or low by normalizing 
miR-155-5p expression to that of normal tissue (expression of miR-155-5p in normal 
tissue=1, high>1, low<1). Data from FFPE tissue samples and patients’ clinical 
characteristics, including treatments for OSCC, were used for multivariate analysis of 
prognostic variables by Cox regression analysis. Metastasis to cervical lymph nodes 
was excluded from the multivariate analysis because of its obvious contribution to a 
poor prognosis. A two-tailed P value <0.05 was considered to be statistically significant. 
All statistical analyses were performed using JMP for Macintosh version 11.  
 
Results 
High miR-155-5p expression was associated with poor overall survival in OSCC 
patients 
To determine the clinical significance of miR-155-5p expression, tissue samples from 
patients with OSCC and those without cancer were collected, prepared for FFPE, and 
analyzed by qRT-PCR. The miR-155-5p levels were then compared with patients’ 
clinical characteristics, to look for significant correlations (n=73; Table 1) after 
confirmation that there were no statistically significant differences in expression of 
miR-155-5p between each site. Mann-Whitney U and Chi-square tests showed that 
high miR-155-5p expression was positively correlated with cervical lymph-node 
metastasis in OSCC patients (Fig 1 a, b). Kaplan-Meier survival analysis of miR-155-5p 
expression and OSCC recurrence or metastasis showed a significant correlation between 
high miR-155-5p expression and a poor disease-free survival rate (p=0.017, Fig 1 c). In 
addition, multivariate analysis of prognostic variables in OSCC patients identified 
miR-155-5p expression as the specific factor leading to a poor OSCC prognosis 
(P=0.023, Table 2).  
 
miR-155-5p was upregulated in OSCC cells 
To determine which miRNAs are differentially expressed in HSC-3 cells, we analyzed 
84 miRNAs by microarray, using the Human Pathway Finder miRNA PCR Array: 
MIHS-102Z (Fig 2 a-c). We found that miR-146a-5p, miR-10b, miR-155-5p, and 
miR10a-5p were upregulated more than 4-fold in HSC-3 cells. Conversely, 38 miRNAs 
were downregulated, albeit less than 4-fold (Fig 2 b). Furthermore, the expression of 
miR-155-5p was 8.04-fold higher in the HSC-3 cells than in the HaCaT cells (Fig 2 c). 
 
Effect of miR-155-5p mimic or inhibitor on OSCC-cell proliferation and migration 
We investigated correlations between miR-155-5p and the ability of HSC-3 cells to 
proliferate and migrate by assaying cell proliferation and wound-healing migration in 
cells transfected with a miR-155-5p mimic or inhibitor. We first confirmed that 
transfection was successful by performing qRT-PCR for miR-155-5p. Proliferation did 
not differ markedly between HSC-3 cells transfected with the miR-155-5p mimic or the 
inhibitor (Fig 3 a). Furthermore, although there was no statistically significant 
difference, the migratory ability of HSC-3 cells tended to increase by the miR-155-5p 
mimic and to decrease by the miR-155-5p inhibitor (Fig 3 b). Together, our data suggest 
that miR-155-5p may affect the ability of HSC-3 cells to migrate rather than their ability 
to proliferate. 
 
Effect of miR-155-5p on E-cadherin, N-cadherin, and vimentin mRNA expression 
To investigate correlations between miR-155-5p and the mRNA of genes related to 
epithelial or mesenchymal properties, we analyzed E-cadherin, N-cadherin, and 
vimentin in HSC-3 cells transfected with miR-155-5p inhibitor. E-cadherin was 
significantly upregulated in HSC-3 cells transfected with the miR-155-5p inhibitor (Fig 
4 a). In contrast, N-cadherin and vimentin tended to be downregulated in HSC-3 cells 
transfected with the miR-155-5p inhibitor (Fig 4 a).  
 
miR-155-5p inhibitor suppressed the STAT3 signaling pathway through SOCS1 
To identify the biological mechanism by which miR-155-5p inhibitor mediates the 
upregulation of E-cadherin and the downregulation of N-cadherin and vimentin, we 
used qRT-PCR to analyze SOCS1 and STAT3 in HSC-3 cells transfected with 
miR-155-5p inhibitor. We found trends for SOCS1 to be upregulated and STAT3 to be 
downregulated (Fig 4 b).  
 
Discussion 
OSCC's most dangerous characteristic is its potential for metastasis. When removing a 
primary OSCC tumor, surgeons may also remove nearby lymph tissue—especially 
cervical lymph nodes, as these are frequently the first metastasis sites. Once OSCC 
metastasizes to the lymph system, the likelihood of a favorable outcome decreases 
significantly. Our study suggests that miR-155-5p induces metastasis to the lymph 
nodes, which leads to a poor prognosis. Thus, miR-155-5p might be a useful prognostic 
biomarker and an important therapeutic target for OSCC.  
High levels of miR-155-5p were significantly associated with a poor 
prognosis, metastasis to cervical lymph nodes, and poor overall survival. Multivariate 
analysis confirmed that this association of miR-155-5p with a poor prognosis for OSCC 
was not influenced by other prognostic variables such as treatment, pTNM stage, or age. 
Therefore, miR-155-5p merits consideration as a potential prognostic biomarker.      
Analysis by miRNA microarray confirmed that the miR-155-5p levels were 
high in OSCC cell lines compared with HaCaT cells. The roles of miR-155 upregulation 
and EMT in metastasis have been investigated in several cancers (22-23). We 
hypothesized that miR-155-5p also plays a crucial role in OSCC metastasis through 
EMT and could serve as a novel target for OSCC treatment. To investigate 
miR-155-5p's effect on OSCC cell proliferation, migration, and expression of 
EMT-related mRNAs, we conducted a series of loss- and gain-of-function assays with a 
miR-155-5p mimic or inhibitor. Our data showed that increased miR-155-5p function 
caused trends toward enhanced OSCC-cell migration rather than enhanced proliferation. 
Recently, miRNAs have been found in serum, plasma, saliva, and other body 
fluids. In addition, circulating extracellular vesicles, such as exosomes, containing 
miRNA are significantly associated with treatment resistance, metastatic properties, and 
a poor prognosis (24-26). These findings suggest that the effect of miRNAs is not 
limited to the cancer cell itself, but that miRNAs can influence the behavior of both 
neighboring and distant cells. In other words, miRNAs exert not only autocrine effects, 
but also paracrine or endocrine effects. The miRNAs contained in exosomes influence 
the microenvironment of cells in the stroma of the neoplasm, including endothelial cells 
and fibroblasts, permitting them to begin migrating and invading other tissues (24). This 
mechanism may explain why the changes in the HSC-3 cells’ migration were not 
statistically significant, even though a clear relationship between metastasis and the 
expression of miR-155-5p was shown in clinical samples.   
In HSC-3 cells transfected with miR-155-5p inhibitor, the epithelial marker 
E-cadherin was upregulated while the mesenchymal markers N-cadherin and vimentin 
decreased. During EMT, epithelial makers are progressively lost as mesenchymal 
markers increase, and the cells develop a mesenchymal phenotype (4). However, one 
fundamental function of miRNA is to silence mRNAs by cleaving their target mRNA 
strand or by decreasing the efficiency of its translation into protein. Thus, we 
hypothesized that miR-155-5p induced EMT by inhibiting an unknown biological 
mechanism. This would explain the high levels of epithelial-related mRNAs in HSC-3 
cells transfected with miR-155-5p inhibitor and the high miR-155-5p levels in both the 
HSC-3 cell line and the FFPE tissue samples. This would also support the potential for 
developing a novel OSCC therapeutic agent based on miR-155-5p function.  
A recent study reported a STAT3-mediated association between miR-155 and 
EMT that leads to invasion and metastasis (21). In head and neck squamous cell 
carcinoma, previous study reported SOCS1 regulates STAT3 activation in cell line 
and tissue samples (27) and STAT3 alternation correlates poor prognosis (28). Our 
results suggest that miR-155-5p inhibitor may suppress EMT by downregulating STAT3 
via SOCS1 upregulation. Both increased SOCS1 and decreased STAT3 were observed 
in HSC-3 cells transfected with miR-155-5p inhibitor, suggesting that inhibited 
miR-155-5p function downregulates STAT3 by activating SOCS1, as previously 
described (16). STAT3 activation has been associated with EMT in several carcinomas 
(17). Thus, miR-155-5p inhibitor may function as an EMT suppressor that increases 
SOCS1 expression and suppresses STAT3 signaling. (Fig 5)  
Taken together, our findings indicate that the induction of metastasis and the 
poor prognosis associated with high miR-155-5p expression may be a direct result of 
EMT. Although our results indicate that miR-155-5p merits consideration as a 
prognostic biomarker and a treatment target, the details of the mechanism by which 
miR-155-5p exerts its effects remain obscure. Furthermore, we have evaluated the 
function of miRNA only at the miRNA and mRNA levels, and since the no significant 
differences for N-cadherin, Vimentin, STAT3 and SOCS1 mRNA, it is only 
speculations that miR155-5p contributes to EMT through STAT3 signaling 
pathway via SOCS1 in HSC-3 cell. Further studies of OSCC, specifically focusing on 
mRNA translation to protein, will be necessary to determine the mechanism underlying 
miR-155-5p’s association with poor prognosis in more detail. Additionally, Only 73 
OSCC specimens from 5 different sites and 5 controls from gingiva were included 
to this study. Aithough there was no statistically significant difference of 
miR-155-5p expression between each biopsy site, some factors may affect our 
results depending on which site in the oral cavity the biopsy is taken. Larger 
number of patients and comparison of each biopsy site may improve the study 
quality. 
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Figure legends 
Table 1: Clinical characteristics of patients with OSCC 
 
Figure 1: High expression of miR-155-5p is associated with OSCC metastasis to neck 
lymph nodes and poor prognosis for OSCC. (a) High miR-155-5p levels are found in 
tissue samples from OSCC patients with metastasis to neck lymph nodes (*P< 0.05). (b) 
miR-155-5p levels in FFPE tissue samples from patients with OSCC correlate with 
metastasis to neck lymph nodes. Significance of correlation between miR-155-5p 
expression in FFPE tissue samples and the clinical index (presence or absence of 
metastasis) are determined by Chi-square test (P=0.04). (c) Kaplan-Meier survival 
analysis support the correlation between a poor disease-free survival rate for OSCC 
patients and high miR-155-5p expression (P=0.017).  
 
Table 2: Cox-regression multivariate analysis of prognostic variables in OSCC patients 
 
Figure 2: miR-155-5p expression in HSC-3 cells. miRNA microarray analysis of 84 
miRNAs that are expressed differently in HSC-3 versus HaCaT cells. (a) miR-155-5p 
express more strongly in HSC-3 cells than HaCaT cells (black arrow). Clustergram 
generated from miRNA microarray data of HaCaT and HSC-3 cells. Red: high 
expression; green: low expression; levels are continuously mapped on the color scale at 
the bottom of the figure. (b) miR-155-5p expression is 8.04-fold higher in HSC-3 cells 
than HaCaT cells. Scatterplot generated from miRNA microarray data from HaCaT and 
HSC-3 cells. (c) miR-155-5p expression is significantly higher in HSC-3 cells than 
HaCaT cells (*P<0.05).    
 
Figure 3: Effect of miR-155-5p regulation on the proliferation and migration of HSC-3 
cells. (a) Proliferation assay of HSC-3 cells transfected with a miR-155-5p mimic or 
inhibitor. There are no significant differences in HSC-3 cell proliferation in either 
condition. (b) Wound-healing migration assay of HSC-3 cells. HSC-3 cells’ migration is 
increased by transfection with a miR-155-5p mimic and decreased by transfection with 
an miR-155-5p inhibitor, but the difference is not statistically significant.  
 
Figure 4: Effect of miR-155-5p inhibitor on the expression of EMT related mRNA. (a) 
E-cadherin expression is significantly increased in HSC-3 cells transfected with an 
miR-155-5p inhibitor (*P<0.05). HSC-3 cells transfected with an miR-155-5p inhibitor 
shows trends toward decreased N-cadherin and vimentin expression. (b) SOCS1 
expression tend to be upregulated in HSC-3 cells after transfection with the miR-155-5p 
inhibitor, while STAT3 expression tend to be downregulated. 
 
Figure 5: SOCS1 is potential target of miR-155-5p. miR-155-5p is associated with EMT 
through STAT3-signaling modulation via SOCS1. (a) The seed region of miR-155-5p 
shows good complementarity to the SOCS1 3’UTR. (b) miR-155-5p induces EMT by 
upregulating STAT3 via SOCS1 downregulation. 
 
 
Patient characteristics
Number of patients 
(total n=73)	
miR-155-5p expression
Cancer / normal	
P value	
High 
expression	
Low 
expression	
n=30	 n=43	
Age
＜60 18 7 11 0.48
≧60 55 23 32
Gender
Male 49 21 28 0.15
Female 24 9 15
T-primary tumor
T1, 2 37 14 23 0.60
T3, 4 36 16 20
N-regional lymph node
N(−) 42 13 29 0.045*
N(+) 31 17 14
pTNM stage
Ⅰ-Ⅱ 29 11 18 0.60
Ⅲ-Ⅳ 44 19 25
Treatment
Surgery only 24	 9 15 0.57
Surgery + preoperative therapy 41	 17 24 0.94
Radiotherapy only 3	 2 1 0.28
Chemotherapy + radiotherapy 3	 1 2 0.96
Unknown 2 1 1 0.87
*P<0.05.
Table 1	
Patient characteristics
Number of 
patients
(total n=73)	
Hazard ratio	 P value	
Expression of miR-155-5p
High 30 5.156 0.023*
Low 43
Age
0.845 0.358	
pTNM stage
I	 13	 1.097	 0.778	
II	 16	
III	 10	
IV 34
Treatment
Surgery only 24	 2.480 0.115	
Surgery + preoperative therapy 41	 1.363 0.243
*P<0.05.
Table 2	
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